Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 10796555
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis

  2025cites this paper
• Ten-Year Trend in 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients with Ulcerative Colitis: An Analysis of Korean Health Insurance Data.

  2025cites this paper
• Mesalazine-associated lung fibrosis: case report and literature review

  2025cites this paper
• Management and treatment optimization of patients with mild to moderate ulcerative colitis

  2023cites this paper
• A systematic review and meta‐analysis of outcomes after elective surgery for ulcerative colitis

  2020cites this paper
• Emerging therapies for the treatment of ulcerative colitis

  2020cites this paper
• ERKRANKUNGEN DER VERDAUUNGSORGANE

  2020cites this paper
• Targeting IL‐10, ZO‐1 gene expression and IL‐6/STAT‐3 trans‐signaling by a combination of atorvastatin and mesalazine to enhance anti‐inflammatory effects and attenuates progression of oxazolone‐induced colitis

  2020cites this paper
• The Role of Immunopathology: As Predictor Factors in Patients with Inflammatory Bowel Diseases

  2020cites this paper
• Mesalamine in the Initial Therapy of Ulcerative Colitis.

  2020cites this paper
• Role of Fecal Microbiota Transplantation for Maintenance of Remission in Patients with Ulcerative Colitis: A Pilot Study.

  2019cites this paper
• Optimierung der konservativen (Nichtbiologika‑)Therapie bei chronisch-entzündlichen Darmerkrankungen

  2019cites this paper
• Sodium selenite ameliorates both intestinal and extra-intestinal changes in acetic acid-induced colitis in rats

  2018cites this paper
• Immunomodulatory tetracyclines: Facing the complexity of intestinal inflammation

  2017cites this paper
• Usefulness of sulfasalazine for patients with refractory-ulcerative colits

  2016cites this paper
• Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.

  2015cites this paper
• Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity.

  2014cites this paper
• Novel Formulations and Dosing Strategies for 5-ASA A Summary of Selected Recent Worldwide

  2013cites this paper
• Vedolizumab as induction and maintenance therapy for ulcerative colitis.

  2013cites this paper
• Altered Colonic Mucosal Polyunsaturated Fatty Acid (PUFA) Derived Lipid Mediators in Ulcerative Colitis: New Insight into Relationship with Disease Activity and Pathophysiology

  2013cites this paper
• Aktuelle Diagnostik und Therapie der Colitis ulcerosa – Update

  2012cites this paper
• Guidelines for the management of inflammatory bowel disease in adults

  2011cites this paper
• Drug therapy for ulcerative colitis.

  2011cites this paper
• Comparison of oral prednisone and prednisone combined with metronidazole for induction therapy of canine inflammatory bowel disease: a randomized-controlled trial.

  2010cites this paper
• Guidelines for the management of inflammatory bowel disease in children in the United Kingdom.

  2010cites this paper
• Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD.

  2010cites this paper
• Dose level and dosing method of steroids for moderate ulcerative colitis

  2010cites this paper
• Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD.

  2009cites this paper
• Common Pitfalls in Management of Inflammatory Bowel Disease

  2009cites this paper
• Aktuelle Diagnostik und Therapie der Colitis ulcerosa

  2008cites this paper
• Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome

  2008cites this paper
• Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis

  2008cites this paper
• Management of inflammatory bowel disease in adults

  2007cites this paper
• Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis

  2007cites this paper
• Positioning biologic therapy for Crohn’s disease and ulcerative colitis

  2007cites this paper
• Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.

  2007cites this paper
• Practical guidelines for the treatment of inflammatory bowel disease.

  2007cites this paper
• Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis

  2006cites this paper
• Management of Perianal and Fistulizing Crohn's Disease

  2006cites this paper
• Comparison of the efficacy and safety of Eudragit‐L‐coated mesalazine tablets with ethylcellulose‐coated mesalazine tablets in patients with mild to moderately active ulcerative colitis

  2006cites this paper
• Review article: high‐dose aminosalicylates to induce and maintain remissions in ulcerative colitis

  2006cites this paper
• Combined oral and topical mesalazine treatment for extensive ulcerative colitis

  2006cites this paper
• Systematic review: adherence issues in the treatment of ulcerative colitis

  2006cites this paper
• Inflammatory Bowel Disease: Therapy for Active Disease

  2006cites this paper
• Once daily MMX mesalazine for the treatment of mild‐to‐moderate ulcerative colitis: a phase II, dose‐ranging study

  2006cites this paper
• The 'polypill', friend or foe?

  2005cites this paper
• Traitement de la rectocolite ulcro-hmorragique dans sa forme tendue (colite grave exclue)

  2004cites this paper
• The management of mild to severe acute ulcerative colitis

  2004cites this paper
• Inflammation in the ileal pouch: Associated factors and long-term prognosis

  2004cites this paper
• Guidelines for the management of inflammatory bowel disease in adults

  2004cites this paper
• In vivo evaluation of a novel pH‐ and time‐based multiunit colonic drug delivery system

  2004cites this paper
• [Management of idiopathic proctitis].

  2004cites this paper
• Ulcerative colitis: conservative management and long-term effects

  2004cites this paper
• Chronisch-entzündliche Darmerkrankungen - Therapie

  2004cites this paper
• [Induction and maintenance of remission in ulcerative colitis].

  2004cites this paper
• Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

  2004influential citation
• Mesalazine (5‐aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis – results from a randomized‐controlled trial

  2004cites this paper
• [TNF-alpha inhibitors in inflammatory bowel disease].

  2004cites this paper
• Traitement préventif de la rechute au cours de la rectocolite ulcéro-hémorragique

  2004cites this paper
• Mesalamine derivatives in the treatment of Crohn's disease.

  2004cites this paper
• General principles of medical therapy of inflammatory bowel disease.

  2004cites this paper
• Epidermal growth factor for ulcerative colitis.

  2003cites this paper
• on Pathogenesis and Progress in Management of IBD XXIst European of

  2003cites this paper
• Treatment of inflammatory bowel disease in childhood: best available evidence.

  2003cites this paper
• on Pathogenesis and

  2003cites this paper
• Inflammatory Bowel Disease Principles and Practice

  2003cites this paper
• Medical management of ulcerative colitis.

  2003cites this paper
• Appendicectomy and ulcerative colitis

  2003cites this paper
• Corticosteroids in Crohn’s disease

  2002cites this paper
• Konservative Standardtherapie der Colitis ulcerosa

  2002cites this paper
• [Not Available].

  2002cites this paper
• Neue und alte Therapieoptionen bei ankylosierender Spondylitis – gibt es eine Indikation für Sulfasalazin?

  2002cites this paper
• Standardtherapie der Colitis ulcerosa

  2002cites this paper
• Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

  2002cites this paper
• A double‐blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis

  2002cites this paper
• A double‐blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis

  2002cites this paper
• Evolving medical therapies for ulcerative colitis

  2001cites this paper
• Evolving treatment strategies for inflammatory bowel disease.

  2001cites this paper
• Medical management of inflammatory bowel disease: old and new perspectives

  2001cites this paper
• Extended Abstracts of the Lectures

  year unknowncites this paper